RespireRx Pharmaceuticals — Cannabinoid summit, Boston, December 10-12, 2018
22 slides from RespireRx Pharmaceuticals's conference presentation, Dec 10, 2018
Slide 1: Pharmaceutical Development of Cannabinoid Medicines: Opportunities and Challenges
December 10th - 12th 2018 | Boston, USA — R e R Ss Ad RespireRx te Pharmaceuticals Inc. Phonnaceuticots Summit De — Pharmaceutical Development of Cannabinoid Medicines: Opportunities and Challenges Richard Purcell SVP RED RespireRx Pharmaceuticals December 10, 2018
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer WA RespireRx el Inc This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act") and the Company intends that such forw
Slide 3: Market research sources
"Areview Market Research and BDS Analytics Lee tah 2 Brightview Group
Slide 4: CBD Products are Everywhere!
CBD Products are Everywhere! $820 Million U.S. Hemp-Based Product Sales by Category in 2017 Food 5% > ~ Hemp CBD . =a k » 23% oe ' —— | Industrial iy IN y Applications 18% Supplements = pp = Other Consumer \ Products 2% Personal Care 22% Consumer Textiles 13% Source: Hemp Business Journal estimates
Slide 5: The Laws and Regulations for Cannabinoids are Confusing
The Laws and Regulations for Cannabinoids are Confusing Example: In California Marijuana is Legal as per Prop 64 But CBD is Illegal!! Until the FDA rules that industrial hemp-derived CBD oil and CBD products can be used as a food or California makes a determination that they are safe to use for huma
Slide 6: Cannabinoids From Hemp vs Cannabis
Cannabinoids Fram Hemp vs Cannabis Federal Law Prohibits the Growing, Sale, and Distribution of Cannabis, Hemp & Their Derivatives > The DEA considers both marijuana and hemp and their derivatives (including THE and CBD) to be Schedule | drugs > THC is separately listed as a Schedule | drug Ai = > T
Slide 7: CBD Manufacturers are Ramping up Production to Meet Growing Demand
CBD Manufacturers are Ramping up Production to Meet Growing Demand The 2018 Farm Bill Holds the Key to the Future of CBD If passed, the 2018 Hemp Farming Act will: |. Legalize the cultivation of industrial hemp across the USA, making CBD products legal in all 50 states 2. Remove hemp and CBD from th
Slide 8: The FDA Oversees the Regulatory Approval of Cannabinoids as Drugs
The FDA Oversees the Regulatory Approval of Cannabinoids as Drugs As per the FDA, the Path to Development of Cannabiniod Pharmaceutical & Medicinal Products is the Same as the Normal Development Path for any Pharmaceutical Drug Product Development Phase || Preclinical! > | Phase “safe” | Phasell“ffc
Slide 9: Many Medicines are Derived from Plants and Microbes
Many Medicines are Derived from Plants and Microbes Over the last 34 years, the 33% of All Drugs Approved by FDA are Derived from Natural Products and Botanicals 50 45 40 35 0 25 20 15 10 % of NCE Approvals at FDA Designated as N, NB, or ND* w * Note: N’:Natural product, unmodifed in structure, thou
Slide 10: FDA Approves Marijuana Derived Medicine Epidiolex
dune 25, 2018 FDA Approves (* Marijuana Derived Medicine 3 Epidiolex° pharmaceuticals «annabidiol)@ Approved for Dravet syndrome and Lennox-Gestaut syndrome, two rare forms of childhood epilepsy Derived from CBD extracted from Cannabis grown in the U.K. Oral solution that has undergone rigorous clin
Slide 11: Wide Ranging Therapeutic Opportunities for Cannabinoids
Wide Ranging Therapeutic Opportunities for Cannabinoids oAN) RespireRx Clinicaltrials.gov lists 139 clinical trials of cannabidiol and 282 trials for cannabinoids* ADHD Anxiety Appetite Autism Bipolar Disorder Cancer Cerebral Palsy Cervical Dystonia COPD Crohn's Disease Depression Epilepsy & Seizure
Slide 12: FDA Regulatory Pathways for Cannabinoid Drugs
FDA Regulatory Pathways for Cannabinoid Drugs As per the FDA, the Path to Development of Cannabiniod Pharmaceutical & Medicinal Products is the Same as the Normal Development Path for any Pharmaceutical Drug Product FDA has Stated that THE and CBD Products are Excluded from the Dietary Supplement De
Slide 13: The FDA Regulatory Path for Generic Products
The FDA Regulatory Path for Generic Products The Abbreviated New Drug Application - ANDA SYNDROS® FDA-approved liquid dronabinol + fast absorption INSYS + flexible dosing ’ sae 4.2 mg of SYNDROS? = 5 mg Dronabinol gel cap (Marinol®) é SYN DROS. Oral formulation provides comparable systemic exposure
Slide 14: RespireRx is Developing Dronabinol for the Treatment of Obstructive Sleep Apnea
RespireRx is Developing Dronabinol for the Treatment of Obstructive Sleep Apnea o Dronabinol Overview = Dronabinol is a synthetic form of delta-9-THC, the psychoactive molecule in cannabis = Rx drug approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients un
Slide 15: Protect Your Intellectual Property with Patents
Protect Your Intellectual Property with Patents RespireRx Holds the Patents for Cannabinoids in the Treatment of Sleep Related Breathing Disorders Dronabinol for OSA is Patent Protected + Issued Method-of-Use Patents: “Functional Role for Cannabinoids in Autonomic Stability During Sleep" - Patent 7,
Slide 16: Secure the API Supply Chain
Secure the AFI Supply Chain Dronabinol API is a Schedule | Drug with Manufacturing and Import Quotas Dronabinol API Suppliers Form Location Noramco* 20% Sesame Oil or Ethanol = Norac (Alkem/S&B Pharma) Resin USA Johnson-Matthey Oil or Ethanol UK Rhodes Technologies 10% Sesame Oil USA Insys Resin USA
Slide 17: Formulation of Cannabinoid Products & Differential Routes of Administration
Formulation of Cannabinoid Products & Differential Routes of Administration* Technology Advantage Examples Sesame Oil Gel Caps Appraved as Schedule Ill drug grain is : . Versafilm Dronabinol Buccal Film/Tablet Bypass I* Pass Metabolism ekliadlietia, Oral Solution Rapid Onset of Action Syndras@i (Oro
Slide 18: PACE: A Phase 2B Clinical Trial
PACE: A Phase ZB Clinical Trial: Pharmacotherapy of Apnea by Cannabimimetic Enhancement Principle Investigators + Dr. David Carley at University of llnois - Chicago & Dr. Phylis Zee at Northwestern University Study Design * — Randomized, Placebo-controlled, Parallel Groups, Multi-site Trial in Patie
Slide 19: The PACE Trial Replicates the Phase 2A Study
The Pace Trial Replicates the Phase ZA Study! oa) RespireRx hpi so rer Inc The Published Literature Can be used to Support a 505(b)2 NDA for Dronabinol in OSA ** p<.02, compared to placebo for Phase 2A Two Phase 2 Trials Have Shown that Dronabinol Treatment Results in a Statistically Significant, Do
Slide 20: FDA Expedited Approval Opportunities & RespireRx Dronabinol for OSA
FDA Expedited Approval Opportunities & RespireRx* Dronabinol for OSA Breakthrough Therapy Preliminary clinical data Designation Accelerated Approval Pathway Not specified: Sponsor should make justification of alternate endpoint based scientific support Prionty Review Designation D2 Containdin the na
Slide 21: Financial Planning & Commercial Strategy Workshop: Topics for Discussion
Financial Planning & Commercial Strategy Workshop FW RespireRx Pharmaceuticals Inc Developing Cannabinoids: Topics for Discussion + Federal & state laws +» Hemp & cannabis products + FDA requirements for Rx development +» DEA constraints on supply + Extracts vs purified compounds +> OTC supplements
Slide 22: Pharmaceutical Development of Cannabinoid Medicines: Opportunities and Challenges
December 10th - 12th 2018 | Boston, USA — R e R Ss Ad RespireRx te Pharmaceuticals Inc. Phonnaceuticots Summit De — Pharmaceutical Development of Cannabinoid Medicines: Opportunities and Challenges Richard Purcell SVP RED RespireRx Pharmaceuticals December 10, 2018
RespireRx Pharmaceuticals — Cannabinoid summit, Boston, December 10-12, 2018 on 6ix